Identifying and defusing weapons of mass inflammation in carcinogenesis.
The continued cancer risks associated with chronic inflammation necessitate the identification of inflammatory molecules and the cancer pathways they affect. Evidence indicates that there are multiple mechanisms linking inflammation to cancer and that there are multiple targets for chemoprevention. Here, we review some of the key factors and the cancer pathways they disturb as a necessary prerequisite to the identification of targets for chemoprevention.
Hofseth
Lorne J
LJ
Department of Basic Pharmaceutical Sciences, College of Pharmacy, Coker Life Sciences, University of South Carolina, Columbia, SC 29208, USA. hofseth@cop.sc.edu
Ying
Lei
L
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016718:Arachidonic Acid / Q000378:metabolism; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000378:metabolism*; D005609:Free Radicals / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D009369:Neoplasms / Q000209:etiology / Q000378:metabolism* / Q000517:prevention & control; D009569:Nitric Oxide / Q000378:metabolism; D012307:Risk Factors
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D005609:Free Radicals; D016718:Arachidonic Acid; D009569:Nitric Oxide